不良事件报告

如果发生不良事件,患者应始终寻求医生或药剂师的建议。

如果您想向ELC Group s.r.o.报告不良事件,请在下面找到联系信息:

+420 224 910 672

(欧洲中部时间09.00-17.30)

+420 226 251 459

(24/7不间断)

有关其他任何问题,请与我们联系:

+420 22 491 0000或我们的 区域办事处。

Hlášení nežádoucích príhod

Pacienti by meli vždy požádat o radu svého lékare nebo lékárníka v prípade výskytu nežádoucích príhod.

Pokud chcete nahlásit nežádoucí príhodu spolecnosti ELC Group s r.o., prosím využijte kontaktních údaju níže:

+420 224 910 672

(09.00-17.30 CET)

+420 226 251 459

(non-stop 24/7)

Pro záležitosti, které se netýkaji farmakovigilance, kontaktujte prosím recepci:

+420 22 491 0000 nebo naše další pobočky.

ELC Group signs 1.5 million Euro regulatory affairs contract with Chinese pharma giant

Landmark deal ELC Group’s Concept to Commercialisation solution approach

Cambridge, UK, 21 April, 2015 – ELC Group, one of the fastest-growing providers of regulatory affairs services, today announces that it has been awarded a 1.5 million Euro contract by one of China’s biggest pharmaceutical companies.

The contract award is a major endorsement of ELC Group’s new Concept to Commercialisation solution approach, which delivers a highly integrated portfolio of regulatory affairs consultancy services to customers, from the development stage through to the implementation of clinical trials, completion of product registration, and successful marketing of the product.

The major project, which will see two products taken through ELC Group’s end-to-end Concept to Commercialisation service, is expected to be complete by the end of 2016. The customer, one of the top 25 Chinese pharmaceutical companies, is an active pharmaceutical ingredient company that is moving towards the finished formulation business.

ELC Group was successfully selected for the contract following a rigorous qualification process, which compared ELC Group against a number of other domestic and international Clinical Research Organisations (CROs). The key measurement criteria included experience, quality of work, timeline, costing and working culture. The client was impressed by ELC Group’s comprehensive Concept to Commercialisation model and confident that ELC Group could be relied on to support their crucial international market expansion plan. Additionally, open communication, common language and cultural understanding were key factors that helped ELC to stand out in the tendering process as the ultimate partner.

Commenting on the landmark deal, ELC Group CEO Marco Rubinstein said: “Breaking boundaries is becoming a norm for ELC Group, and this landmark contract award marks an exciting new level for us, both in size and scope of projects.” He added: “This latest deal really validates our Concept to Commercialisation partnership approach and its strengths in delivering end-to-end support to customers targeting ambitious growth.”

相关新闻